Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | KIF18A | Q8NI77 | 4/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25518454 | 0.80 | CDK1 (0.37) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23833647 | 0.78 | CHRNB2 (0.38) | ABL1CDK1CDK2KDR | |
| SCHEMBL23833536 | 0.77 | HTT (0.43) | KDM4EGAAMAPTLMNAFEN1 | |
| SCHEMBL23833549 | 0.77 | PDIA6 (0.39) | KDM4EGAAMAPTCA12CA1 | |
| SCHEMBL30094638 | 0.77 | L3MBTL1 (0.42) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL30096914 | 0.77 | PDIA6 (0.39) | KDM4EGAAMAPTCA12CA1 | |
| SCHEMBL23833547 | 0.77 | L3MBTL1 (0.42) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23845592 | 0.72 | KDM4E (0.51) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23833576 | 0.71 | KDM4E (0.55) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23845547 | 0.68 | KDM4E (0.54) | KDM4EGAAMAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | KDM4E 69/4885GAA 3851/4885ABL1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.